C-F1AYTrestle Biotherapeutics
stem cells, biofabrication, implantable tissue
replacementreplacingtissue engineered
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-F1AY
C-F1AYC-F1AYstem cells, biofabrication, implantable tissue
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Bioprinting - 3DPrint.com | Additive Manufacturing Business Site Sponsor: Log In | Register Data & Research PRO Content Advertise Instant 3D Printing Quote Search --> Site Sponsor: News View All News Data & Analysis --> Bioprinting, Medical and Dental 3D Software 3D Scanning Aerospace Education Metals Materials Editorials/Opinions Exclusive Interviews Podcast 3D Printing News Briefs, June 27, 2026: Nanoscale 3D Printing, Defense Readiness, & More US Army Awards Continuous Composites 3D Printed Missile Component Contract Why Qualification Is Becoming the Next Frontier for AM in Energy Zone … ng the Next Frontier for AM in Energy About / Team Advertise Newsletter Contact/Submit Search Data & Research PRO Content Advertise Instant 3D Printing Quote Log In Register The Bioprinting Zone Bioprinting World Map 3D Systems Bioprinting 101 Medical & Dental News e-NABLE Prosthetics ROKIT A Bioprinting World Map With 109 established bioprinting companies and many entrepreneurs around the world showing interest in the emerging field, it’s just a matter of time before it beco
Y Combinator's biotech startups incubate a new generation of therapies and tools | TechCrunch –:–:–:– The first StrictlyVC of 2026 hits SF on April 30. Tickets are going fast. Register now. Founder Summit ticket savings of up to $190 end June 26. Join 1,000+ founders and VCs for all-day bootcamp. REGISTER NOW. Close TechCrunch Desktop Logo TechCrunch Mobile Logo Latest Startups Venture Apple Security AI Apps Disrupt 2026 Events Podcasts Newsletters Search Submit Site Search Toggle Mega Menu Toggle Topics Latest AI Amazon Apps Biotech & Health Climate Cloud Comp … . Forcyte’s team is published in Nature, and received a $2.5 million SBIR award from the NIH, a pretty rare endorsement. Kilobaser is taking aim at the growing DNA synthesizing space; companies often contract with dedicated synthesizing labs to create batches of custom DNA molecules, but at a small scale this might be better done in-house. Kilobaser’s benchtop machine makes the process as simple as using a copier, even for people with no technical know-how. As lon … nd microfluidic chip (sold by the company, naturally), it can replicate DNA you submit digitally in less than two hours. This could accelerate testing in many a small lab that’s held back by its reliance on a separate facility. The company has already sold 15 machines at €15,000 each — but like razor blades, the real money is in the refills. Reshape Biotech is perhaps the most straightforward of the bunch. Its approach to automating common lab tasks is to create custom
%PDF-1.4 %���� 1 0 obj > endobj 3 0 obj > endobj 8 0 obj > endobj 9 0 obj > stream x��]Yo�~������>� ����s��r,`d����%Q�g��t�ף� x�l�(��U�NH������ ��W�x�����_����t�d�#.�w��?!������|��o�|�� .� O��q��g�����������ϗ� �����������X?w��:���3� 1-g�%,) ~'i2n����1F}7i �k�$��5���|� nǕt�z��G;����'⯀�jq������̇="g`z�e���g��Q������wb(jB��`O0�] ��y�h��^3/ y1��g�@��{)R�� �^�J>��}�k�����b����sj.;���VuC�B�b���d) �D�j��!t�N�{���F� 1�>ɳ�b�Mݶ�0�����f��0���ACf;��mtd_��q�u� ���c��ZvA���Zx7���������6�b�D�ݭ3����lEp����Ŗ�BS{J�I� 8]l���l_A�2��`}m"�&�yÂ��� �4����GIdwև�R- � … �fu�������.wW�6i���F��D��� �d�]�j^� �w�f�ư��� �Qٕ$e�EP.�m_����ЬI�J)���RFP��ł����� [� Z6�!Z���N4���D��3�qMa$@oG��x��4h���a�x��-̀�l#6]�)9B��I,��Θ�(-� ��vda��/T�'��`������ʮ_�X�ѣt��h +V������9)�P���Ä����#XPK�#C���PK(�9o~��(�D4m�$�#M |�J�$wB!�"يt6 iK�0�3[�*^U62y&����(�9ߔ�:W-8��(���u�2=_ y )U�/�S�˺0nL�b�U��q��vZ���Й�ܘ�/���w��j$1Z�� �\���ŵ�hT����z� �a�;sγ}��Xj��5]� B�( n�9�xC��3���������� c���k�m�J�ǫhf�R�� Ӵz�=�L%��aL5Ьa� �±A�D}�r$`��|���D�
Genitourinary Collaboration and Licensing Agreements --> Accessibility: Skip TopNav Genitourinary Collaboration and Licensing Agreements Benchmark Report 2026: Access to Structured Analysis of 316 Deals Across Development Pathways, Therapeutic Approaches, and Commercial Strategies This report provides a comprehensive and structured analysis of 316 genitourinary collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market. May 19, 2026 04:24 ET | Source: Research and Markets Research and Markets … Medical Columbia University Cook Biotech Corino Therapeutics Danish Innovation Fund Datavant DaVita Debiopharm Defense Threat Reduction Agency DemeTECH Department of Veterans Affairs Dialco Medical Dicerna Pharmaceuticals DILIsym Services Dimerix Biosciences Diurnal Drexel University Duchesnay Ecole Polytechnique Federale de Lausanne eGenesis EirGen Pharma Eledon Pharmaceuticals Elexopharm Eliaz Therapeutics Eli Lilly Enable Injections Eversana Evestra Evotec Exagen Diagnost … GLOBE NEWSWIRE) -- The "Optical Sorter Market by Offering, Type, Platform, Application - Global Forecast to 2032" has been added to ResearchAndMarkets.com's offering. The... Read More June 26, 2026 09:34 ET | Source: Research and Markets Furniture Plastic Industry Intelligence Report 2026-2030: Market Dynamics, Case Studies, Competitive Insights Dublin, June 26, 2026 (GLOBE NEWSWIRE) -- The "Furniture Plastic Market by Plastic Type, Composition, Furniture T … he "Furniture Plastic Market by Plastic Type, Composition, Furniture Type, Application, End-use Industry, and Region - Global Forecast to 2030" has been... Read More
Stem Cell Collaboration and Licensing Deals 2010-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscriptions Expert Net … logies Celulas Genetica Censo Biotechnologies Center for iPS Cells Research and Application Centogene Centre for Commercialization of Regenerative Medicine (CCRM) Centre for Drug Research and Development (CDRD) Cephalon Cesca Therapeutics CFD Research CHA Bio & Diostech Charite-Universitatsmedizin Charles River Laboratories ChemDiv Chemizon Children's Hospital Boston Children's Hospital of Orange County Children's Research Institute China Cord Blood China PharmaHub China Sout … aT Pharma Macquarie University Magenta Therapeutics Maryland Stem Cell Research Fund Maryland Technology Development Corporation Massachusetts General Hospital Matricel Maxcyte Mayo Clinic McEwen Centre for Regenerative Medicine McGill University McKesson MD Anderson Cancer Center Medac Medexus Pharmaceuticals Medical College of Wisconsin Medical Research Council Medical Technology Enterprise Consortium Medical University South Carolina Medistem Mekonos Memorial Sloan Ketteri … rker Discovery Stemmatters Stemnion Stempeutics Steven M. Schwartzberg Memorial Fund Stryker Superview Biotechnology Swedish Orphan Biovitrum SwitchGear Genomics Synterys System Biosciences Taconic Biosciences TaiGen Biotechnology TaiRx Takara Bio Takeda Pharmaceutical TAP Biosystems Targazyme Taxus Cardium Pharmaceuticals Technology Strategy Board (UK) Technology University Dresden Teijin Temple University Terumo Blood and Cell Technologies TET Systems Teva Pharmaceutical In … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector T
false 0001357459 DEF 14A 0001357459 2025-01-01 2025-12-31 0001357459 2023-10-31 2025-01-01 2025-12-31 0001357459 ecd:PeoMember 2025-01-01 2025-12-31 0001357459 ecd:NonPeoNeoMember 2025-01-01 2025-12-31 0001357459 ecd:PeoMember 2024-01-01 2024-12-31 0001357459 ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001357459 2024-01-01 2024-12-31 0001357459 ecd:PeoMember 2023-01-01 2023-12-31 0001357459 ecd:NonPeoNeoMember 2023-01-01 2023-12-31 0001357459 2023-01-01 2023-12-31 0001357459 ecd:PeoMember PALI:GrantDateFairValueOfStockAwardsAndOptionAwardsGrantedInFiscalYearMember 2025-01-01 2025-12-31 00013574 … f Other Than the Registrant)   Payment of Filing Fee (Check all boxes that apply):   ☒ No fee required ☐ Fee paid previously with preliminary materials ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11               PALISADE BIO, INC. 4600 South Syracuse Street, Suite 900 Denver, Colorado 80237   NOTICE OF ANNUAL MEETING OF STOCKHOLDERS   To Be Held on … www.proxydocs.com/PALI , where you will be able to listen to the meeting live, submit questions and vote. You will need to register at www.proxydocs.com/PALI in order to attend the Annual Meeting virtually. You will need to have the 12-digit control number which is included in the Notice of Internet Availability of Proxy Materials (“Notice”), on your proxy card or on the instructions that accompanied your proxy materials to join the virtual Annual Meeting. You wi … il the director’s earlier death, resignation or removal. We refer to this proposal as the “Director Election Proposal” or “Proposal 1.”       2. To ratify the appointment of Baker Tilly US, LLP, as our independent registered public accounting firm for the fiscal year ending December 31, 2026. We refer to this proposal as the “Auditor Ratification Proposal” or “Proposal 2.”       3. To approve … capital stock of the Company from 307,000,000 to 457,000,000. We refer to this proposal as the “Increased Authorized Shares Proposal” or “Proposal 3.”       4. To approve the Amended and Restated Palisade Bio, Inc. 2021 Equity Incentive Plan. We refer to this proposal as the “Incentive Plan Proposal&#
%PDF-1.7 %���� 680 0 obj > endobj 702 0 obj >/Filter/FlateDecode/ID[ ]/Index[680 110]/Info 679 0 R/Length 110/Prev 1643733/Root 681 0 R/Size 790/Type/XRef/W[1 2 1]>>stream h�bbd``b`)�� B H���� � �L@�� H0l� n4H"H� �?��� �y��S� >stream h�b```�� � �� � ��ea�h`3���J�Ľ������d. �x�W k>�[�Ӓ �%�ؚ}: endstream endobj 681 0 obj >/Metadata 71 0 R/Names 705 0 R/OpenAction[682 0 R/FitH 910]/Outlines 776 0 R/PageLabels 674 0 R/PageLayout/SinglePage/PageMode/UseOutlines/Pages 676 0 R/Threads 703 0 R/Type/Catalog/ViewerPreferences >>> endobj 682 0 obj > endobj 683 0 obj >stream … �����^�蜄KpZ0[�o��;r}���s��MӠ&BJ�p�1�C �����wii�I�j��颲����ӭ�m � >stream application/postscript doi:10.1016/j.jses.2017.08.002 Iatrogenic rerouting of the lateral antebrachial cutaneous nerve during distal biceps tendon repair: a case report Thuan Ly MD Itai Pasternak MD Claudia Meuli-Simmen MD Flavien Mauler MD JSES Open Access, 1 (2017) 139-140. doi:10.1016/j.jses.2017.08.002 Biceps tendon Repair Complication Nerve compression Nerve rerouting Lateral antebrachial cut … -17T11:51:11-05:00 2022-12-17T11:51:11-05:00 Acrobat Distiller 10.0.0 (Windows) application/pdf doi:10.1016/j.trsl.2022.06.012 Elsevier Inc. Translational Research, 250 (2022) 1-17. doi:10.1016/j.trsl.2022.06.012 Kidney organoids: a pioneering model for kidney diseases MURAT Tekguc RONALD C. VAN GAAL SEBASTIEN G.M. UZEL NAVIN GUPTA LEONARDO V. RIELLA JENNIFER A. LEWIS RYUJI MORIZANE uuid:fd8cfc10-4791-4a8b-8025-00abb91efa0c uuid:52eb6d43-7bf4-124f-b0b1-e3481ed7e92a journal ©
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
%PDF-1.4 %���� 3703 0 obj > endobj xref 3703 26 0000000016 00000 n 0000002979 00000 n 0000003180 00000 n 0000003218 00000 n 0000004341 00000 n 0000004860 00000 n 0000005051 00000 n 0000005166 00000 n 0000007143 00000 n 0000008734 00000 n 0000010228 00000 n 0000011984 00000 n 0000014044 00000 n 0000016067 00000 n 0000017972 00000 n 0000020322 00000 n 0000020512 00000 n 0000022893 00000 n 0000023240 00000 n 0000023344 00000 n 0000024244 00000 n 0000024516 00000 n 0000029770 00000 n 0000029811 00000 n 0000002744 00000 n 0000000833 00000 n trailer ]/Prev 4881227/XRefStm 2744>> startxref 0 %%EOF 37 … 0f84ae2dba8 xmp.did:494c9918-49c2-4156-85d8-1ad3ced75664 default converted from application/x-indesign to application/pdf Adobe InDesign 19.5 (Macintosh) / 2024-07-26T10:21:58-05:00 application/pdf Adobe PDF Library 17.0 False 1 False False 8.500000 11.000000 Inches ProximaNova-Semibold Proxima Nova Semibold Open Type Version 3.001;PS 003.001;hotconv 1.0.88;makeotf.lib2.5.64775 False Mark Simonson - Proxima Nova Semibold.otf ProximaNova-Bold Proxima Nova Bold Open Type Versio … ) 2020-07-31T13:24:35+10:00 2020-07-31T13:24:35+10:00 2020-07-31T13:24:35+10:00 application/postscript bit_bio_logo_cmyk Fred Nerby xmp.did:eef38016-4dc2-45aa-b20c-6f70e5f56489 xmp.iid:eef38016-4dc2-45aa-b20c-6f70e5f56489 xmp.did:4f7f6ccd-bb1a-4a4a-95e7-c6cae84b363e proof:pdf xmp.iid:912c6a85-d3d9-4f05-b006-3b359894f9dd xmp.did:912c6a85-d3d9-4f05-b006-3b359894f9dd xmp.did:4f7f6ccd-bb1a-4a4a-95e7-c6cae84b363e proof:pdf saved xmp.iid:4f7f6ccd-bb1a-4a4a-95e7-c6cae84b363e 2020-04 … 7 2020-04-14T16:14:56+01:00 Adobe Illustrator 24.1 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:f106f99e-6d68-4d10-90c2-bfdf241c514f 2020-07-13T11:52:10+10:00 Adobe Illustrator 24.2 (Macintosh) / saved xmp.iid:3b0ffbbe-52e5-4ae3-afba-5cbb2fd89c38 2020-07-17T10:30:37+10:00 Adobe Illustrator 24.2 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript … t to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:a36fa6d7-40a4-4900-9c19-9235e48db470 2020-07-30T20:06:41+10:00 Adobe Illustrator 24.2 (Macintosh) / saved xmp.iid:eef38016-4dc2-45aa-b20c-6f70e5f
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
ARMI partners with Museum of Science, Boston to showcase biofabrication. | Advanced Regenerative Manufacturing Institute (ARMI) | BioFabUSA posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Ag … tive Manufacturing Institute, founded by Dean Kamen and launched with a pivotal grant from the Department of Defense, brings together industry, academics and civic leaders from across the country to advance health innovation, all from an epicenter in Manchester, NH. In fact, this thriving region of the Manufacturing USA network is now called Regen Valley, and it's a hub for cutting edge health technologies. Here in Region Valley, a vibrant team is working to transform the fut … diseases. At the time, almost no one understood his work. Investors refused to fund him, his papers were rejected dozens of times, and his research findings went unrecognized. Yet he remained steadfast in his conviction: “If you want to have a big impact, you have to be willing to take big risks.” (To make a profound impact, you must dare to take enormous risks.) A Revolution from Lab to Operating Room Langer's persistence ultimately yielded a breakthrough. His biodegradable … dy according to a predetermined schedule— This principle later found widespread application in cancer drug delivery systems, insulin pumps, smart implants, and other devices. These innovations not only catalyzed the interdisciplinary convergence of modern medical device manufacturing, but also propelled the technological evolution of companies like Boston Scientific, Moderna, and Becton Dickinson. His research transformed “devices” from mere machinery into “intelligent entiti
%PDF-1.5 %���� 594 0 obj >/Metadata 107 0 R/PageLayout/OneColumn/Pages 593 0 R/StructTreeRoot 138 0 R/Type/Catalog>> endobj 107 0 obj >stream 2020-03-02T10:37:35-08:00 2018-12-23T10:21:08+11:00 2020-03-02T10:37:35-08:00 Acrobat PDFMaker 11 for Word uuid:9440eff6-0ea1-48e0-ab47-46b02da8af83 uuid:396b4311-1dd2-11b2-0a00-d200980989ff 5 application/pdf Will Higgins Adobe PDF Library 11.0 D:20181222232043 Microsoft endstream endobj 593 0 obj > endobj 138 0 obj > endobj 141 0 obj > endobj 139 0 obj > endobj 140 0 obj > endobj 298 0 obj [142 0 R 143 0 R 144 0 R 145 0 R null null 341 0 R null null nul
Trestle Biotherapeutics Wins Prestigious KidneyX Prize | Trestle Biotherapeutics Team News Contact Menu Menu Trestle Biotherapeutics Wins Prestigious KidneyX Prize June 12, 2023 San Diego-based Trestle Bio named one of KidneyX Artificial Kidney Prize Phase 2 winners SAN DIEGO [June 12, 2023] – Trestle Biotherapeutics today received a $1 million prize from the KidneyX Innovation Accelerator through the organization’s Artificial Kidney Prize program. Trestle is one of eight Artificial Kidney Prize Phase 2 winners announced today. Trestle was recognized for their innovative approach in developing … ition by the team at KidneyX is fantastic and the financial support the Phase 2 prize provides is really impactful to our efforts to bioengineer kidney tissues that could one day replace dialysis. We’re equally excited to be partnering with leaders at HHS and ASN. This is an exceptional group and a unique opportunity for us to engage with the agencies leading such important work for patients with diseases of the kidney,” Dr. Shepherd continued. Of the work being done at Trest … in and help accelerate their progress in meaningful ways.” Trestle will use the prize funds to advance their pre-clinical R&D efforts to scale early prototype designs and demonstrate increasing levels of functionality within those bioengineered tissues. About Trestle Biotherapeutics Trestle Biotherapeutics, Inc. is a pre-clinical stage company developing bioengineered therapies for patients living with end stage renal disease. Once implanted, these bioengineered stem cell … replacement organs. Learn more at trestlebio.com . About The Artificial Kidney Prize The Kidney Innovation Accelerator ( KidneyX ), a public-private partnership between the U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN), is accelerating innovation in the prevention, diagnosis, and treatment of kidney diseases. The Artificial Kidney Prize is a competition to accelerate the development of continuous kidney replacement therapies
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Trestle Biotherapeutics licenses kidney implant 3D bioprinting technology from Harvard - 3D Printing Industry Trestle Biotherapeutics licenses kidney implant 3D bioprinting technology from Harvard News 3D Scanners Aerospace Business Education Market Insights Medical & Dental Transport Talleres Artificio Adopts SHINING 3D Scanning to Cut Inspection Times Paloma Duran 2 weeks ago 0 The New All Rounder Revopoint POP 4 3D Scanner Now on Kickstarter: Technical Specifications and Pricing Ada Shaikhnag 2 months ago 0 Revopoint launches MetroY Ultra and opens POP 4 Kickstarter sign-ups Anyer Tenor
RAPID + TCT: The Evolution of Additive Manufacturing | Advanced Regenerative Manufacturing Institute (ARMI) | BioFabUSA LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or
--> Kidney Engineering Technology for New Tissue Replacement Therapies Skip to Main Content Wyss Institute Menu Search Site Who We Are About How We Work How We Collaborate Team Careers Contact Our Work Technologies Impact Report Publications Collaborations AI DataHub Brain Targeting Program Collaborative Fund Alliance Diagnostics Accelerator Global Development Program Nucleic Acid Delivery Consortium Northpond Labs Alliance Scientific Instrumentation Program Newsroom News Press Resources Multimedia Events Give Search Past Success - Licensing Kidney Engineering Technology for New Tissue Replace … rt Publications Collaborations AI DataHub Brain Targeting Program Collaborative Fund Alliance Diagnostics Accelerator Global Development Program Nucleic Acid Delivery Consortium Northpond Labs Alliance Scientific Instrumentation Program Newsroom News Press Resources Multimedia Events Give Close menu -->
Trestle Biotherapeutics announces license agreement with Kumamoto University for key stem cell biology technology for regenerative medicine (Opens in new tab) (Opens in new tab) (Opens in new tab) Login Join Free Fields & Topics Life Sciences All Content Applications & Methods News & Articles Videos Events & Summits Webinars Drug Discovery & Development Biopharmaceuticals Basic Research Target Discovery Lead Discovery Pre-Clinical Development Clinical Development Drug Manufacturing Clinical Diagnostics All Content Clinical CE Webinars CLINICAL24 Applications & Methods N … events Editorial Features Immersive Content Resources SelectScience eBooks All application eBooks Life Sciences Drug Discovery Clinical Diagnostics Environmental Materials Food & Beverage General Lab Lab Automation Lab Informatics Separations Spectroscopy Forensics Cannabis Testing How-to-Buy eBooks Applications & Methods All Applications & Methods Life Sciences Drug Discovery Clinical Diagnostics Environmental Materials Food & Beverage General Lab Lab Automa … , or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification. Bioprocessing / Fermentation Bioprocessing is the use of biological materials to perform commercial, scientific or medical research processes. Biological materials used include cells, enzymes and organisms. Usually bioprocessing requires a batch or continuous bioreactor such as a fermentor or cell culture system. The advantages of using a rea … rticles Nominate your favorite new lab product of 2025 for a Scientists’ Choice Award 2 Jan 2026 Single-molecule proteomics platform reveals biology’s hidden players 26 Jun 2025 biocrates life sciences ag becomes part of Bruker Group 4 Jun 2025 (Opens in new tab) (Opens in new tab) (Opens in new tab) Fields & Topics Life Sciences Drug Discovery & Development Clinical Diagnostics Environmental Materials Food & Beverage General Lab Lab Automation Lab Informatics Sep … events Editorial Features Immersive Content Resources SelectScience eBooks All application eBooks Life Sciences Drug Discovery Clinical Diagnostics Environmental Materials Food & Beverage General Lab Lab Automation Lab Informatics Separations Spectroscopy Forensics Cannabis Testing How-to-Buy eBooks Applications & Methods All Application
Baxter Announces Definitive Agreement to Divest Its Vantive Kidney Care Segment to Carlyle for $3.8 Billion | Baxter Skip to main content Utility Menu News Investors Careers Partners and Suppliers Contact Us Global Site Main Menu Patients Healthcare Professionals Perspectives Our Story Our Products & Services Search Search Healthcare Professionals Committed to helping you enhance your practice and the experience of your patients through connected devices and digitalised data sharing. Healthcare Professionals Primary Care Supporting every aspect of your clinical practice, including physical
Trestle Corp - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Trestle Corp Subsidiary Company | California, United States Subsidiary Company | California, United States Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 100 Clinical Results associated with Trestle Corp Login to view more data 0 Patents (Medical) associated with Trestle Corp Login to view more data 2 Literatures (Medical) associated with Trestle Corp 01 Ju … un 2023 · www.businesswire.com Trestle Biotherapeutics Wins Prestigious KidneyX Prize SAN DIEGO--( BUSINESS WIRE )-- Trestle Biotherapeutics today received a $1 million prize from the KidneyX Innovation Accelerator through the organization’s Artificial Kidney Prize program. Trestle is one of eight Artificial Kidney Prize Phase 2 winners announced today. Trestle was recognized for their innovative approach in developing bioengineered kidney tissues for patients living with kid … ition by the team at KidneyX is fantastic and the financial support the Phase 2 prize provides is really impactful to our efforts to bioengineer kidney tissues that could one day replace dialysis. We’re equally excited to be partnering with leaders at HHS and ASN. This is an exceptional group and a unique opportunity for us to engage with the agencies leading such important work for patients with diseases of the kidney,” Dr. Shepherd continued. Of the work being done at Trest … in and help accelerate their progress in meaningful ways.” Trestle will use the prize funds to advance their pre-clinical R&D efforts to scale early prototype designs and demonstrate increasing levels of functionality within those bioengineered tissues. About Trestle Biotherapeutics Trestle Biotherapeutics, Inc. is a pre-clinical stage company developing bioengineered therapies for patients living with end stage renal disease. Once implanted, these bioengineered stem cell-der … replacement organs. Learn more at trestlebio.com . About The Artificial Kidney Prize The Kidney Innovation Accelerator ( KidneyX ), a public-private partnership between the U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN), is accelerating innovation in the prevention, diagnosis, and treatment of kid
Harvard University licenses kidney engineering technology to Trestle Biotherapeutics to facilitate new kidney replacement therapies Skip to main content Main navigation Academics Faculty & Research News Events Offices & Services About Us Information For Alumni Industry Partners & Recruiters Prospective Students Shortcuts Employment & Jobs Visit Us Make a Gift Search Search Menu News News Events All News Stories Harvard University licenses kidney engineering technology to Trestle Biotherapeutics to facilitate new kidney replacement therapies Powerful combination of 3D bioprintin
Nature Outlook Highlights Research in the Fight Against Chronic Kidney Disease | Trestle Biotherapeutics Team News Contact Menu Menu Nature Outlook Highlights Research in the Fight Against Chronic Kidney Disease March 8, 2023 Trestle Co-Founder and CSO, Alice Chen, Ph.D., provides insight on the fields of kidney stem cell biology and regenerative medicine, and how Trestle is advancing bioengineered kidney tissues for patients with kidney failure. How organoids are advancing the understanding of chronic kidney disease Back to News Copyright 2026 © Trestle Biotherapeutics Scroll to top Scroll to
“Solving the hardest problems is where we start.” 🚀 – Alice Chen, Trestle Bio Wellcome Leap’s HOPE Program Wellcome Leap uses a proven model adapted from DARPA to systemically stack the odds in… | Wellcome Leap LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any … comment, sign in Imperial Enterprise 9,897 followers 5mo Report this post ⏱️👀 Deadline this week for collaboration funding: https://hubs.ly/Q03-l6gc0 Extending our exciting partnership between Imperial College London and Nanyang Technological University Singapore , researchers from either institute can apply for £60,000 of funding on 'blue skies' projects working with partners from either the UK or Singapore in the following areas: 🏥Health & Society 🎨Culture, Organisa
Trestle Bio Announces Research Collaboration with Humacyte | Alice Chen, PhD | 16 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Linked
Trestle Biotherapeutics — YC Company Profile | Altss For Asset Classes Solutions Compare Case Studies Blog Book a demo Home / YC Companies / Trestle Biotherapeutics YC W21 Trestle Biotherapeutics Bioengineered kidneys for patients with kidney failure www.trestlebio.com About We are developing an implantable therapeutic tissue that will be surgically delivered to patients suffering from end stage renal disease. Upon implantation, this tissue will supplement the patient's renal function, eliminating their dependency on dialysis and improving their disease status. This has the potential to n … Preqin Altss vs PitchBook Altss vs FINTRX Altss vs Dakota Company About us Why Submit Data How we Collect Data Press Careers Contribute Submit your firm Submit a deal Submit a fund
Meet Jessica Bendell, a Project... - United Therapeutics Facebook Log In United Therapeutics's Post United Therapeutics December 16, 2024 · Shared with Public Meet Jessica Bendell, a Project Manager at #IVIVA , a United Therapeutics company, who blends her passion for novel medical solutions with her process engineering expertise to drive groundbreaking advancements in bioartificial kidney technology. Jessica plays a vital role in coordinating efforts between the engineering and cell biology teams, ensuring seamless collaboration as they work toward developing fully implantable bioartific
Tom York on Business: Startup Advisory Montford Ventures Opens San Diego Office We’re in the homestretch! Every dollar gets us closer to our $10,000 goal by June 30. DONATE Close DONATE NEWSLETTER Search for: Search All Topics Latest Home Arts Business Health Immigration Politics Events Tiempos Neighborhood News Open dropdown menu Beach and Bay Press (Pacific/Mission Beach) Downtown News La Jolla La Mesa Courier Mission Times (Navajo/College Area) Peninsula Beacon (Pt.Loma/Ocean Beach) Uptown News About Staff Contact Media Kit Real Estate Obituaries Guides Print Editions ASU NEWSWELL Facebook … 2019. The tourism tax revenues significantly contribute to Oceanside’s general fund, supporting such services as public safety, parks, street repair and homeless outreach. The Visit Oceanside bureau influences about one-third of the $568 million that is generated by visitors and supports 3,500 jobs. * * * Trestle Biotherapeutics says it has received $1 million in prize money from the KidneyX Innovation Accelerator through its artificial kidney prize program. Trestle, d … patients living with end-stage renal disease, is one of eight artificial kidney prize Phase 2 winners announced recently. The company says more than 800 million patients around the planet suffer from chronic kidney disease. In the United States alone, 125,000 kidney failures are diagnosed each year, and 600,000 patients depend on dialysis, a technology developed more than 65 years ago. The treatment costs in the U.S. exceed $100 billion annually. KidneyX is a public-private p
%PDF-1.6 %���� 44445 0 obj > endobj 44468 0 obj >/Filter/FlateDecode/ID[ ]/Index[44445 38]/Info 44444 0 R/Length 112/Prev 1556321/Root 44446 0 R/Size 44483/Type/XRef/W[1 3 1]>>stream h�bbd```b``�"7�I?�f�IW�4L��O@$�7X�v�f f����l'0{��S`s�A��*�T{"���$�E4��������a�H �� ����/~e endstream endobj startxref 0 %%EOF 44482 0 obj >stream h�b```�� � r � ce`a���@ X���큕� �K����emk\��tAz��� 6NN�f����U :Cx�10?j�p�8P�`tB���[#S�9cH�_�q�&���U,�t�.( �| 9�����eC��i ��c��؝�?0�3� (;��䃀 W9Kv�dž7 $ d;�����-k�p�����JGĘ���ʘ� � �Rp����=������聅 Vh�Ș�/a]��z�U!Y�j�0F ǩ��� z … :814d70fb-465d-4344-ae2e-e3d0a53a304b uuid:bc018df0-4c6d-4bdc-a489-006c006d0c83 application/pdf Liz Larabell Adobe PDF Library 24.3.212 endstream endobj 641 0 obj >stream hޜ��n1�_e�@ r�n\��tA 7�a;E�>� @A����H��̹{���7Z�H�\�r��*[U���P��ڇj�Uۭ�6�i�K���.E�a�K�z�Pn%� �\Y ���Ր*���s�o��Q��P���a�e�34n�ۅZ+vwwxx���i� � צY�S��T�����i#����78�}��Xk܋�K^���d�@ Vx �71� �>�#�I�%0�V��@'��,��&��=�sJ�T�jN�k� ��e��'Η'nW���B`!�XV���J`%�j*W���F`#��V���N`'��o�9%�tu���L*�v5 … :814d70fb-465d-4344-ae2e-e3d0a53a304b uuid:88b2f4d4-acab-4bb0-aae4-64eef9e5f1f4 application/pdf American Society of Nephrology ASN Kidney Week 2024 - Disclosures ASN Kidney Week 2024 Adobe PDF Library 24.3.212 endstream endobj 44446 0 obj >/Metadata 640 0 R/Outlines 649 0 R/PageLayout/SinglePage/Pages 44421 0 R/StructTreeRoot 652 0 R/Type/Catalog/ViewerPreferences >>> endobj 44447 0 obj >/ProcSet[/PDF/Text]>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 44483 0 obj >str
%PDF-1.6 %���� 683 0 obj > endobj 706 0 obj >/Filter/FlateDecode/ID[ ]/Index[683 33]/Info 682 0 R/Length 113/Prev 449145/Root 684 0 R/Size 716/Type/XRef/W[1 3 1]>>stream h�bbd```b``f� A$�D�2�v�9 � L���e��lI0�,[f��H!-� �� 2u&�dl7����f�DrrA��y ��{ #�X#Q��؟yLQ endstream endobj startxref 0 %%EOF 715 0 obj >stream h�b```g``z������ Ȁ�@1V �x�p���� � ` �U�[�7�X�|������X�����U" l3���(��E,���i��ਠ젹@�G�C&;��� �+�/``8q��l:C�۴E' �"�S Ne`�i ��Hl۬t���=��g`��U `Z�*� endstream endobj 684 0 obj >/Metadata 29 0 R/OCProperties >/OCGs[707 0 R]>>/Outlines 37 0 R/PageLayout/Singl … :0ed0bcd2-ae41-4653-99d7-c5cfa2c5236e uuid:30eb0ff1-4540-4e92-9f49-8ad09d98d34c application/pdf PowerPoint Presentation Anna Matras Adobe PDF Library 24.2.23 0x010100CCC0F366534B11499F4CCA82FBA9CAB2 6bbc7097-0ae0-49ce-b9ae-f1468f58c993 endstream endobj 30 0 obj >stream h�2�0T0P���w�/�+Q0���L)�6�0�)BHc� RY�� ���Zlg`��� endstream endobj 31 0 obj >stream h�l�Mk�@���8�� !�+�����4u�f�Ϳ璉�R�:��T5%@��YË�I�,��T����-�p���`��"H)�gUU2���R65��FȦ��Σ �[:0��(��B�8�� �
Trestle Biotherapeutics | Storyboard Job Board The StoryHouse Jobs Board Welcome to the StoryHouse Jobs Board, a place to explore career adventures at start-ups and companies founded by Claremont alumni and the Claremont community. Choose your next adventure at a company where you’ll have an edge from day one, and leverage our Claremont network to build your career. Also, make sure to check out our newsletter, StoryHouse Review , to find out more about these companies in the Claremont ecosystem. Search jobs Explore companies Join talent network Talent My job alerts Trestle Biotherapeutics tres
Jobs at Trestle Biotherapeutics | Consider You are using an outdated browser. Please upgrade your browser to improve your experience and security. Home Sign In Powered by Consider Privacy Terms
--> Untitled Skip to Main Content Wyss Institute Menu Search Site Who We Are About How We Work How We Collaborate Team Careers Contact Our Work Technologies Impact Report Publications Collaborations AI DataHub Brain Targeting Program Collaborative Fund Alliance Diagnostics Accelerator Global Development Program Nucleic Acid Delivery Consortium Northpond Labs Alliance Scientific Instrumentation Program Newsroom News Press Resources Multimedia Events Give Search Search results 105 Results for '3D Organ Engineering' Technologies (10) Collaborations (0) Team (0) News (68) Pages (0) Multimedia (27) … redefining the fields of medical reconstruction and aesthetics with an initial application of their groundbreaking technology on breast reconstruction and... Video/Animation Reimagine the World – Volume 4 – ReConstruct Edition Denise Skok, a two-time breast cancer survivor, Luba Perry, a scientist at the Wyss Institute, and Samuel Lin, a plastic surgeon collaborating with the Wyss Institute, are all working to reimagine a world where breast cancer patients have b … rt Publications Collaborations AI DataHub Brain Targeting Program Collaborative Fund Alliance Diagnostics Accelerator Global Development Program Nucleic Acid Delivery Consortium Northpond Labs Alliance Scientific Instrumentation Program Newsroom News Press Resources Multimedia Events Give Close menu -->
Portfolio Team Strategy News Investor Login Portfolio Team Strategy News Investor Login W. Michael Gallatin, Ph.D. Senior Advisor Mike is a Senior Advisor on the Frazier Life Sciences team and has co-founded multiple Frazier investments, including Mavupharma and Calistoga. Mike has been a member of the Frazier Life Sciences team since 2006 and brings over 35 years of experience as a scientist and executive to the team. He has co-founded multiple Frazier portfolio companies, including Mavupharma (acquired by AbbVie), Inipharm, Calistoga Pharmaceuticals (acquired by Gilead Sciences), and Stromed
Trestle named as one of CONNECT San Diego’s “Cool Companies” for 2022 | Trestle Biotherapeutics Team News Contact Menu Menu Trestle named as one of CONNECT San Diego’s “ Cool Companies ” for 2022 April 5, 2022 SAN DIEGO [April 5, 2022] – Trestle Biotherapeutics announced today that is has been selected as a “Cool Company” by Connect San Diego, an organization that helps promote San Diego’s top startups for funding. Launched in 2015, Cool Companies is an annual capital program to match San Diego’s top-performing technology and life sciences companies with quality investors. Since the program’s
Trestle Biotherapeutics Announces Formation of Advisory Board - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Rel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Trestle Biotherapeutics Announces Formation of Advisory Board February 23, 2022 | 3 min read Twitter LinkedIn Facebook Email Print Trestle Biotherapeutics, a private, San Diego-based company developing bioengineered therapies for patients living with kidney failure today announced the formati … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Trestle Biotherapeutics Wins Prestigious KidneyX Prize - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases A … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Trestle Biotherapeutics Wins Prestigious KidneyX Prize June 12, 2023 | 3 min read Twitter LinkedIn Facebook Email Print Trestle Biotherapeutics received a $1 million prize from the KidneyX Innovation Accelerator through the organization’s Artificial Kidney Prize program. San Diego-based Trestle Bio named o … ize program. San Diego-based Trestle Bio named one of KidneyX Artificial Kidney Prize Phase 2 winners SAN DIEGO--( BUSINESS WIRE )-- Trestle Biotherapeutics today received a $1 million prize from the KidneyX Innovation Accelerator through the organization’s Artificial Kidney Prize program. Trestle is one of eight Artificial Kidney Prize Phase 2 winners announced today. Trestle was recognized for their innovative approach in developing bioengineered kidney tissues for patients … ition by the team at KidneyX is fantastic and the financial support the Phase 2 prize provides is really impactful to our efforts to bioengineer kidney tissues that could one day replace dialysis. We’re equally excited to be partnering with leaders at HHS and ASN. This is an exceptional group and a unique opportunity for us to engage with the agencies leading such important work for patients with diseases of the kidney,” Dr. Shepherd continued. Of the work being done at Trest … in and help accelerate their progress in meaningful ways.” Trestle will use the prize funds to advance their pre-clinical R&D efforts to scale early prototype designs and demonstrate increasing levels of functionality within those bioengineered tissues. About Trestle Biotherapeutics Trestle Biotherapeutics, Inc. is a pre-clinical stage compan
Trestle Bio Announces Research Collaboration with Humacyte - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releas … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Trestle Bio Announces Research Collaboration with Humacyte March 6, 2025 | 4 min read Twitter LinkedIn Facebook Email Print SAN DIEGO--(BUSINESS WIRE)--Trestle Biotherapeutics, Inc., today announced a research collaboration with Humacyte, Inc. ( Nasdaq: HUMA ), a commercial-stage biotechnology platform co … nd biofabrication programs, and this is a natural progression for us. The broad application of Humacyte’s ATEV technology to treat kidney disease patients is clear, and we’re excited to collaborate with Humacyte to start bringing these engineering concepts to life.” About Trestle Biotherapeutics Trestle Biotherapeutics, Inc. is a preclinical stage company developing bioengineered tissues for patients living with end stage renal disease. Once implanted, these bioengineered ste … AV) access for hemodialysis, and peripheral artery disease. A Biologics License Application for the ATEV in the vascular trauma indication was approved by the FDA in December 2024. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medi … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Trestle Biotherapeutics Licenses Innovations from Harvard University to Develop 3D Biofabricated Tissues to Treat Kidney Failure - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Trestle Biotherapeutics Licenses Innovations from Harvard University to Develop 3D Biofabricated Tissues to Treat Kidney Failure February 8, 2022 | 3 min read Twitter LinkedIn Facebook Email Print Trestle Biotherapeutics today announced that it has entered into a license agreement with Harvar … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Trestle Biotherapeutics Stock Price, Funding, Valuation, Revenue & Financial Statements Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & … l. Revenue Sources 6/12/2023 Biz Plan Competition $1M KidneyX Artificial Kidney Prize $XXM 0 FY undefined 3 5/25/2023 Incubator/Accelerator Subscribe to see more $XXM 0 FY undefined 10 4/1/2021 Convertible Note Subscribe to see more $XXM 0 FY undefined 0 1/1/2021 Seed $XXM Subscribe to see more $XXM 0 FY undefined 10 Other Investors Subscribe to see more $XXM 0 FY undefined 10 Date 6/12/2023 5/25/2023 4/1/2021 1/1/2021 Round Biz Plan Competition Incubator/Accelerator Converti … e Note Seed Other Investors Amount $1M $XXM Investors KidneyX Artificial Kidney Prize Subscribe to see more Subscribe to see more Subscribe to see more Subscribe to see more Valuation $XXM $XXM $XXM $XXM $XXM Revenue 0 FY undefined 0 FY undefined 0 FY undefined 0 FY undefined 0 FY undefined Sources 3 10 0 10 10 Learn more by requesting a demo Trestle Biotherapeutics Investors 11 Investors Trestle Biotherapeutics has 11 investors . KidneyX Artificial Kidney Prize invested in T … Rounds Board Seats Type Location 6/12/2023 6/12/2023 KidneyX Artificial Kidney Prize 1 Biz Plan Competition Business Plan Competition DC 5/25/2023 5/25/2023 Wellcome Leap HOPE Program 1 Incubator/Accelerator Incubator/Accelerator California 4/1/2021 4/1/2021 Acequia Capital 1 Convertible Note Venture Capital Washington 00/00/0000 00/00/0000 Y Combinator Subscribe to see more Incubator/Accelerator California Draper Associates Subscribe to see more Venture Capital California F … ding 6/12/2023 5/25/2023 4/1/2021 00/00/0000 Investor KidneyX Artificial Kidney Prize Wellcome Leap HOPE Program Acequia Capital Y Combinator Draper Associates Rounds 1 Biz Plan Competition 1 Incubator/Accelerator 1 Convertible Note Subscribe to see more Subscribe to see more Board Seats Type Business Plan Competition Incubator/Accelerator Ventur
Angel Investor Portfolio: 230+ Startups I Funded (SpaceX, Anthropic + More)
Harvard University licenses kidney engineering technology to Trestle Biotherapeutics to facilitate new kidney replacement therapies (Opens in new tab) (Opens in new tab) (Opens in new tab) Login Join Free Fields & Topics Life Sciences All Content Applications & Methods News & Articles Videos Events & Summits Webinars Drug Discovery & Development Biopharmaceuticals Basic Research Target Discovery Lead Discovery Pre-Clinical Development Clinical Development Drug Manufacturing Clinical Diagnostics All Content Clinical CE Webinars CLINICAL24 Applications & Methods News & … events Editorial Features Immersive Content Resources SelectScience eBooks All application eBooks Life Sciences Drug Discovery Clinical Diagnostics Environmental Materials Food & Beverage General Lab Lab Automation Lab Informatics Separations Spectroscopy Forensics Cannabis Testing How-to-Buy eBooks Applications & Methods All Applications & Methods Life Sciences Drug Discovery Clinical Diagnostics Environmental Materials Food & Beverage General Lab Lab Automa … events Editorial Features Immersive Content Resources SelectScience eBooks All application eBooks Life Sciences Drug Discovery Clinical Diagnostics Environmental Materials Food & Beverage General Lab Lab Automation Lab Informatics Separations Spectroscopy Forensics Cannabis Testing How-to-Buy eBooks Applications & Methods All Applications & Methods Life Sciences Drug Discovery Clinical Diagnostics Environmental Materials Food & Beverage General Lab Lab Automa
Trestle Bio Partners with Humacyte to Revolutionize Kidney Transplant Technology | HUMA Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes … nd biofabrication programs, and this is a natural progression for us. The broad application of Humacyte’s ATEV technology to treat kidney disease patients is clear, and we’re excited to collaborate with Humacyte to start bringing these engineering concepts to life.” About Trestle Biotherapeutics Trestle Biotherapeutics, Inc. is a preclinical stage company developing bioengineered tissues for patients living with end stage renal disease. Once implanted, these bioengineered ste … AV) access for hemodialysis, and peripheral artery disease. A Biologics License Application for the ATEV in the vascular trauma indication was approved by the FDA in December 2024. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medi
--> Untitled Skip to Main Content Wyss Institute Menu Search Site Who We Are About How We Work How We Collaborate Team Careers Contact Our Work Technologies Impact Report Publications Collaborations AI DataHub Brain Targeting Program Collaborative Fund Alliance Diagnostics Accelerator Global Development Program Nucleic Acid Delivery Consortium Northpond Labs Alliance Scientific Instrumentation Program Newsroom News Press Resources Multimedia Events Give Search Search results 55 Results for 'Stem Cell Engineering' Technologies (4) Collaborations (1) Team (0) News (41) Pages (0) Multimedia (9) P … rt Publications Collaborations AI DataHub Brain Targeting Program Collaborative Fund Alliance Diagnostics Accelerator Global Development Program Nucleic Acid Delivery Consortium Northpond Labs Alliance Scientific Instrumentation Program Newsroom News Press Resources Multimedia Events Give Close menu -->
⭐ Issue #94: A 10-Year Overnight Success Subscribe Sign in ⭐ Issue #94: A 10-Year Overnight Success How Claremont grad Jake Heller and his team built the world's first AI legal assistant, a new local information startup founded by a Claremont serial entrepreneur, and Silicon Valley's latest unicorn Jun 22, 2023 1 Share 💬 Welcome to issue #94 of Between the Lines Good morning & happy Thursday. Let’s jump into…you guessed it, AI. It’s the unsolicited yet oddly helpful guest that won’t leave the party and is involved in everything from our mining operations to our lawmaking. This week, Clare … esting story of how Casetext went from a team of just three to spearheading the application of AI in the practice of law. As a student working in the Community Law Clinic at Stanford Law, Jake Heller was struck by how inaccessible legal information was compared to information in other fields. He understood for there to be equal access to justice, there needed to be equal access to the text of the law itself. By early 2013, Heller had been a litigation associate at Ropes & … for more than a year, following a First Circuit Court of Appeals clerkship and fellowship with the Massachusetts Governor’s Office of Legal Counsel. A Silicon Valley native who’d been coding since he was nine, Heller was perplexed by the disparity between outdated legal tech and powerful everyday tech. “I’d spend four nights in a row until 4 AM looking for one specific court case for a client—but I could find a specific style of Thai restaurant within a mile of my house in m … rm — so pay attention, Claremonsters! If any of these roles catch your eye 👀 , apply and mention Between the Lines. Or, if you are an employer looking to hire tip-top Claremont talent, fill out this form to have your jobs featured. 🗣️ Conversations on the Interwebz: This week’s Claremont financing 💸 Congratulations to Claremont grad Kurt House (CMC ‘01) and KoBold Metals , one of Silicon Valley’s latest unicorns ! The mining startup uses data science and machine learning t … tulations to Trestle Biotherapeutics on being among the eight Artificial Kidney Prize Phase 2 winners. Trestle, co-founded by Claremont grad Alice Chen (PO) , was recognized for its innovative approach to developing bioengineered kidney tissues for patients with kidney failure. The company received $1M to continue developing a functional, stem ce
VentureRadar 0){if($('#i_b_toggleMore').hasClass('active')){Search_Elastic();}else{Search_DeconstructSearchString();Search_Elastic(false);event.preventDefault();}}else{event.preventDefault();}}" onclick="this.removeAttribute('readonly');" ontouchstart="this.removeAttribute('readonly');" id="i_t_Search" name="VRSearch" readonly> All Ranked Organisation Names Apps and Links Homepage (myVR) Funding Deals Hub Similar Companies App Articles Manage Account Logout Login Free Sign-up Forgotten your password? By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie … de Therapies; Vaccines; Biotech Show more Show less Updates All Funding Insight Grant Award Conference Competition Research Website Traffic Trend Business InsighT 01 Dec 2020 Website traffic has increased in the past 3 months, up from a ranking of 676,733 to 376,314. Source: Data from alexa.com COVID-19 vaccine tracker - London School of Hygiene & Tropical Medicine Research Report 20 Sep 2020 [BioNTech; Fosun Pharma; Pfizer] listed among those developing/researching a COVID-1 … ene therapy to cost $850,000 per patient | Reuters Source: reuters.com The STEP Award (2011) Award 29 Nov 2011 Category Winner: Finances Source: The STEP Award (2011) Show less Funding Signals VENTURE FUNDED Venture-funding News Venture-funding News Venture-funding News Related Top Ranked Companies Lists Life Sciences Biologics Healthtech Sars-Cov-2 Vaccine Cancer Melanoma Immunotherapy Diagnostics Dna Rna Peptide Therapies Vaccines Biotech Website Archive 2022 2023 2024 2025 … search results. Please select a Type Funding Round Team Products & Technologies Grant Award Conference Competition Other {DETAIL_VALUE} Remove Upgrade for full access You have reached your free usage limit for today. Upgrade to a paid plan for: Unlimited search alerts 250 records per export Unlimited pages and searches Full Access from $ 60.00 per month Upgrade Now Your VentureRadar Business account is now active and your account information has been sent to … nditions Privacy Policy Cookie Policy Contact Us Twitter LinkedIn | Submit a Company Directory of Companies Login Free Sign-up for VentureRadar access or By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie Policy . Free Sign-up for VentureRadar access You must have cookies enabled to create an accou
Trestle Biotherapeutics: Bioengineered kidneys for patients with kidney failure | Y Combinator Open menu About What Happens at YC? Apply YC Interview Guide FAQ People YC Blog Companies Startup Directory Founder Directory Launch YC Library Partners Resources Startup School Newsletter Requests for Startups For Investors Verify Founders Hacker News Bookface Safe Find a Co-Founder Startup Jobs Log in Apply Home › Companies › Trestle Biotherapeutics Trestle Biotherapeutics Bioengineered kidneys for patients with kidney failure Y Combinator Logo Winter 2021 Active Biotech Company Jobs 0 http://www.t
Trestle Biotherapeutics | Bioengineered therapies for Kidney isease. Team News Contact Menu Menu Bioengineered Therapies for Kidney Disease From the Founders Our team has been building a new company that we’re proud to share with you – Trestle Biotherapeutics. The mission at Trestle is something that we’ve been thinking about for a long time, and we believe it will transform the lives of patients with kidney disease. If we get this right, the solutions we develop can be used to help millions of patients suffering from other types of organ failure. The naming of Trestle carries many meanings fo … ution of Washington, Department of Embryology. Alice completed her postdoctoral fellowship at the Harvard Stem Cell Institute with Dr. Douglas Melton, where she was a Jane Coffin Childs and Merck and Company Fellow. Alice has authored over 20 publications spanning developmental and stem cell biology, human 3D bioprinting, and disease modeling. https://trestlebio.com/wp-content/uploads/Alice-Chen-updated.png 500 500 David Anderson /wp-content/uploads/trestle_logo_color.png Dav … . Lewis has received numerous awards, including the Presidential Faculty Fellow Award, the American Chemical Society Langmuir Lecture Award, the Materials Research Society Medal Award, the American Ceramic Society Sosman and Roy Lecture Awards, and the Lush Science Prize. She is an elected member of the National Academy of Sciences, National Academy of Engineering, National Academy of Inventors, and the American Academy of Arts and Sciences. To date, she has co-founded two co … om the University of Texas Health Science Center, San Antonio. He completed his residency at the University of Colorado followed by a clinical and research fellowship in nephrology at Harvard Medical School at the Brigham and Women’s Hospital and Massachusetts General Hospital. https://trestlebio.com/wp-content/uploads/Krishna-Polu-updated.jpg 500 500 David Anderson /wp-content/uploads/trestle_logo_color.png David Anderson 2021-12-21 08:00:42 2024-04-30 14:23:13 Krishna Polu, … ch Collaboration with Humacyte Trestle Biotherapeutics Wins Prestigious KidneyX Prize June 9, 2023 / in News / by David Anderson SAN DIEGO [June 12, 2023] – Trestle Biotherapeutics today received a $1 million prize from the KidneyX Innovation Accelerator through the organization’s Artificial Kidney Prize program. Trestle is one of eight Artificia
--> Harvard University licenses kidney engineering technology to Trestle Biotherapeutics to facilitate new kidney replacement therapies Skip to Main Content Wyss Institute Menu Search Site Who We Are About How We Work How We Collaborate Team Careers Contact Our Work Technologies Impact Report Publications Collaborations AI DataHub Brain Targeting Program Collaborative Fund Alliance Diagnostics Accelerator Global Development Program Nucleic Acid Delivery Consortium Northpond Labs Alliance Scientific Instrumentation Program Newsroom News Press Resources Multimedia Events Give Search Harvard Univ … rt Publications Collaborations AI DataHub Brain Targeting Program Collaborative Fund Alliance Diagnostics Accelerator Global Development Program Nucleic Acid Delivery Consortium Northpond Labs Alliance Scientific Instrumentation Program Newsroom News Press Resources Multimedia Events Give Close menu -->
Trestle Biotherapeutics | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Trestle Biotherapeutics Trestle Biotherapeutics is dedicated to developing bioengineered therapies for patients with kidney failure, aiming to create implantable tissues that can replace dialysis and delay transplantation. Their mission is to transform the lives of patients suffering from organ failure through innovative stem cell biology and 3D biofabrication technologies, bridging scientific disciplines and global expertise to advance regenerative med … ) Show less News & Updates Trestle Biotherapeutics Wins Prestigious KidneyX Prize Trestle Biotherapeutics received a $1 million prize from the KidneyX Innovation Accelerator for their innovative approach in developing bioengineered kidney tissues for patients with kidney failure, aiming to replace dialysis and address the global organ shortage. Trestle Biotherapeutics Joins the Wellcome Leap HOPE Program Trestle Biotherapeutics announced its participation in the Wellcome … ccelerate its development of bioengineered kidney tissues. Trestle Wins KidneyX Prize Trestle Biotherapeutics was awarded a $1 million prize from the KidneyX Innovation Accelerator for its innovative work in developing bioengineered kidney tissues for patients with kidney failure. View All News Show less Similar organizations Browse all ORGANIZATIONS Member Member Member Member Member Member JOIN OUR MAILING LIST Stay Connected with MTEC Keep up with active and upcoming solic
Trestle Bio Announces Research Collaboration with Humacyte | Trestle Biotherapeutics Team News Contact Menu Menu Trestle Bio Announces Research Collaboration with Humacyte March 6, 2025 SAN DIEGO [March 6, 2025] – Trestle Biotherapeutics, Inc., today announced a research collaboration with Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale. Trestle Bio is a preclinical stage company developing bioengineered kidney tissues for patients suffering from end stage renal disease (ESRD). T … nd biofabrication programs, and this is a natural progression for us. The broad application of Humacyte’s ATEV technology to treat kidney disease patients is clear, and we’re excited to collaborate with Humacyte to start bringing these engineering concepts to life.” About Trestle Biotherapeutics Trestle Biotherapeutics, Inc. is a preclinical stage company developing bioengineered tissues for patients living with end stage renal disease. Once implanted, these bioengineered ste … AV) access for hemodialysis, and peripheral artery disease. A Biologics License Application for the ATEV in the vascular trauma indication was approved by the FDA in December 2024. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medi
Trestle Biotherapeutics Team News Contact Menu Menu NEWS Trestle Bio Announces Research Collaboration with Humacyte March 6, 2025 / in News / by eallison SAN DIEGO [March 6, 2025] – Trestle Biotherapeutics, Inc., today announced a research collaboration with Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale. Read more https://trestlebio.com/wp-content/uploads/trestle-humacyte-logo.jpg 1000 1000 eallison /wp-content/uploads/trestle_logo_color.png eallison 2025-03-06 04:45:51 2 … ch Collaboration with Humacyte Trestle Biotherapeutics Wins Prestigious KidneyX Prize June 9, 2023 / in News / by David Anderson SAN DIEGO [June 12, 2023] – Trestle Biotherapeutics today received a $1 million prize from the KidneyX Innovation Accelerator through the organization’s Artificial Kidney Prize program. Trestle is one of eight Artificial Kidney Prize Phase 2 winners announced today. Read more https://trestlebio.com/wp-content/uploads/trestle-kidneyx-logo.jpg 1000 10 … 9 13:46:15 2025-03-05 17:26:44 Trestle Biotherapeutics Wins Prestigious KidneyX Prize Trestle Biotherapeutics Joins the Wellcome Leap HOPE Program May 25, 2023 / in News / by David Anderson SAN DIEGO [May 25, 2023] – Trestle Biotherapeutics today announced that it has joined the Wellcome Leap HOPE program. Read more https://trestlebio.com/wp-content/uploads/Trestle-Leap-logo.png 1000 1000 David Anderson /wp-content/uploads/trestle_logo_color.png David Anderson 2023-05-25 05:0
When traditional transplants... - National Kidney Foundation Facebook Log In National Kidney Foundation's Post National Kidney Foundation Verified account April 7 · Shared with Public When traditional transplants weren’t possible, these brave people chose xenotransplantation and helped shape the future of kidney care. #DonateLifeMonth kidney.org Two Kidney Xenotransplant Recipients Share What It Was Like to Make History All reactions: 20 7 shares Like Comment